Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Pneumatisk kompression mot blodflödesbegränsning för muskelåtervinning

16 november 2026 uppdaterad av: Todd Schroeder, University of Southern California

Jämförelse av effekterna av pneumatisk komprimering och blodflödesbegränsningsterapi på muskelåtervinning

Both BFR and intermittent pneumatic compression are purported to decrease symptoms associated with exercise induced muscle damage (EIMD) that cause delayed onset muscle soreness (DOMS). Blood flow restriction relies on applying pressurized cuffs to the most proximal portion of the limb. Another form of recovery often relied upon is pneumatic compression. The mechanism by which pneumatic compression works is similar to that of a massage, whereby the device progressively increases the pressure on a portion of the limb before releasing and moving further up the limb.The purpose of this study is determine whether BFR or pneumatic compression can be used to decreased DOMS which may indicate enhanced recovery.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Faktisk)

33

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • California
      • Los Angeles, California, Förenta staterna, 90033
        • University of Southern California

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 30 år (Vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • 18-30 years of age
  • Recreationally active population
  • Women should be on a form of hormonal contraception.
  • No current musculoskeletal injuries or pathologies
  • Must answer "yes" to all PAR-Q questions.

Exclusion Criteria:

  • Individuals that routinely train trail running
  • Discomfort when running
  • Deep vein thrombosis
  • Blood clots
  • Cancerous lesions
  • Sensory or mental impairment
  • Unstable fractures
  • Acute pulmonary edema
  • Acute thrombophlebitis
  • Acute congestive cardiac failure
  • Acute infections
  • Episodes of pulmonary embolism
  • Wounds, lesions, infection, or tumors
  • Bone fractures or dislocations
  • Increased venous and lymphatic return
  • Answers "no" to any of the PAR-Q screening questions

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Inget ingripande: Control

The participants will be asked to refrain from exercise 24 hours prior to and following the exercise. Participants will complete all pre-exercise tests (DOMS, CMJ). The exercise consists of running on a treadmill situated at a -10% grade at 9 km/hr (5.59 mph) for 20 minutes. This is proceeded and followed by 5 minute warm-up/cool-down periods.

Those that are allocated to the "control" group, will not receive treatment after the downhill running protocol.

Experimentell: Pneumatic compression

The participants will be asked to refrain from exercise 24 hours prior to and following the exercise. Participants will complete all pre-exercise tests (DOMS, CMJ). The exercise consists of running on a treadmill situated at a -10% grade at 9 km/hr (5.59 mph) for 20 minutes. This is proceeded and followed by 5 minute warm-up/cool-down periods. Those allocated to the "pneumatic compression" group will receive 20 minutes of pneumatic compression at 100 mmHg.

Following downhill running protocol, participants will complete 20 minutes of pneumatic compression at 100 mmHg.

Experimentell: Blood flow restriction

The participants will be asked to refrain from exercise 24 hours prior to and following the exercise. Participants will complete all pre-exercise tests (DOMS, CMJ). The exercise consists of running on a treadmill situated at a -10% grade at 9 km/hr (5.59 mph) for 20 minutes. This is proceeded and followed by 5 minute warm-up/cool-down periods.

Those allocated to the "BFR" group will receive 4 rounds of treatment: 3 minutes will be spent at 100% of resting limb occlusion pressure, followed by 2 minutes of 0% occlusion.

Following the downhill running protocol, participants will complete 4 rounds of treatment: 3 minutes at 100% resting limb occlusion pressure, 2 minutes of 0% resting limb occlusion pressure.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Counter Movement Jump Height
Tidsram: Baseline to immediately following exercise

Participants will be asked to complete three consecutive counter movement jumps with hands on hips. The CMJ will be used as an indirect measure of muscle function.

Baseline to immediately following exercise
Sedentary delayed onset muscle soreness
Tidsram: Baseline to 24-hours following exercise

Using a visual analog scale (0 = no soreness; 10= worst soreness imaginable), participants will be asked to rate their level of soreness while at rest.

Baseline to 24-hours following exercise
Sedentary delayed onset muscle soreness
Tidsram: Baseline to immediately after treatment

Using a visual analog scale (0 = no soreness; 10= worst soreness imaginable), participants will be asked to rate their level of soreness while at rest.

Baseline to immediately after treatment
Active delayed onset muscle soreness
Tidsram: Baseline to 24-hours following exercise

Using an 11-point visual analog scale (0 = no soreness; 10= worst soreness imaginable) , participants will be asked to rate their level of soreness while completing a wall sit.

Baseline to 24-hours following exercise
Active delayed onset muscle soreness
Tidsram: Baseline to immediately after treatment

Using an 11-point visual analog scale (0 = no soreness; 10= worst soreness imaginable) , participants will be asked to rate their level of soreness while completing a wall sit.

Baseline to immediately after treatment
Counter Movement Jump Height
Tidsram: Baseline to immediately following exercise, approximately 30 minutes after baseline

Participants will be asked to complete three consecutive counter movement jumps with hands on hips. The CMJ will be used as an indirect measure of muscle function.

Baseline to immediately following exercise, approximately 30 minutes after baseline
Sedentary delayed onset muscle soreness
Tidsram: Baseline to immediately following exercise, approximately 30 minutes after baseline

Using a visual analog scale (0 = no soreness; 10= worst soreness imaginable), participants will be asked to rate their level of soreness while at rest.

Baseline to immediately following exercise, approximately 30 minutes after baseline
Active delayed onset muscle soreness
Tidsram: Baseline to immediately following exercise, approximately 30 minutes after baseline

Using an 11-point visual analog scale (0 = no soreness; 10= worst soreness imaginable) , participants will be asked to rate their level of soreness while completing a wall sit.

Baseline to immediately following exercise, approximately 30 minutes after baseline
Counter Movement Jump Height
Tidsram: Baseline to 24 hours following treatment

Participants will be asked to complete three consecutive counter movement jumps with hands on hips. The CMJ will be used as an indirect measure of muscle function.

Baseline to 24 hours following treatment

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

15 januari 2024

Primärt slutförande (Faktisk)

1 december 2025

Avslutad studie (Faktisk)

1 maj 2026

Studieregistreringsdatum

Först inskickad

17 september 2024

Först inskickad som uppfyllde QC-kriterierna

5 februari 2025

Första postat (Faktisk)

7 februari 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

19 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

16 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Ja

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera